Catalogo dei prodotti della ricerca

OCCHIPINTI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.198
EU - Europa 771
AS - Asia 338
AF - Africa 17
SA - Sud America 13
OC - Oceania 3
Totale 2.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.174
IT - Italia 290
SE - Svezia 280
SG - Singapore 195
IN - India 84
DE - Germania 38
CN - Cina 29
BG - Bulgaria 25
FI - Finlandia 24
RO - Romania 22
CA - Canada 20
ID - Indonesia 19
IE - Irlanda 19
ES - Italia 17
FR - Francia 8
GB - Regno Unito 8
UA - Ucraina 8
UG - Uganda 8
AR - Argentina 7
MK - Macedonia 7
NL - Olanda 7
TG - Togo 7
DK - Danimarca 5
HU - Ungheria 4
IR - Iran 4
MX - Messico 4
AU - Australia 3
AT - Austria 2
BE - Belgio 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
HK - Hong Kong 2
KR - Corea 2
TR - Turchia 2
AM - Armenia 1
BR - Brasile 1
CH - Svizzera 1
EC - Ecuador 1
GR - Grecia 1
PT - Portogallo 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 2.340
Salva come PNG Salva come JPEG
Città #
Fairfield 183
Singapore 117
Chandler 105
Ashburn 72
Wilmington 67
San Paolo di Civitate 62
Cambridge 60
Rome 57
Seattle 55
Woodbridge 50
Houston 44
Princeton 44
New York 36
Lawrence 35
Sofia 25
Boston 24
Millbury 24
Jakarta 19
Santa Clara 19
Boardman 18
Andover 16
Dearborn 16
Dublin 16
Milan 16
Helsinki 15
Rizziconi 15
San Diego 13
Ann Arbor 12
Beijing 10
Bremen 8
Toronto 8
Valladolid 8
Federal 7
Fremont 7
Lomé 7
Mumbai 7
Norwalk 7
Ottawa 7
Plano 7
Skopje 6
Mannheim 5
Bloomfield 4
Florence 4
Lappeenranta 4
Los Angeles 4
Mantova 4
Marcallo con Casone 4
Mexico City 4
Boca Raton 3
Chicago 3
Guangzhou 3
Leawood 3
Madrid 3
Munich 3
Olgiate Olona 3
Osio Sotto 3
Padova 3
Phoenix 3
Sacramento 3
Scuola 3
Turin 3
Albignasego 2
Anantapur 2
Boydton 2
Brussels 2
Buscate 2
Bühl 2
Calgary 2
Catania 2
Falkenstein 2
Gavirate 2
Grafing 2
Hong Kong 2
Hyderabad 2
Kampala 2
La Penilla 2
Locorotondo 2
London 2
Mariquita 2
Massa 2
Milpitas 2
Montepulciano 2
New Delhi 2
North Shields 2
Palermo 2
Pomezia 2
Redwood City 2
Shanghai 2
Stockholm 2
Sydney 2
Uppsala 2
Angoulême 1
Atlanta 1
Avellino 1
Beauharnois 1
Berlin 1
Bern 1
Beverly Hills 1
Bratislava 1
Brooklyn 1
Totale 1.465
Salva come PNG Salva come JPEG
Nome #
The sexist behaviour of immune checkpoint inhibitors in cancer therapy? 122
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes 99
Degradation rate of 5-fluorouracil in metastatic colorectal cancer. A new predictive outcome biomarker? 98
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX 87
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient 86
Coexistence of three EGFR mutations in an NSCLC patient: A brief report 85
Genetic polymorphism can help physician choosing the best lung cancer chemotherapy 72
The 5-Ws of immunotherapy in head and neck cancer 71
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 71
AIOM abstracts - IMPACT OF MULTIDISCIPLINARY BASELINE EVALUATION FOR THYMIC EPITHELIAL TUMORS: EXPERIENCE FROM AN ITALIAN REFERENCE CENTER 66
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study 64
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 63
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification 62
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 62
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression ≥ 50% and their relationship with clinical outcomes 61
Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong 60
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a network analysis 58
Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment. a case report 57
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 53
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study 49
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 49
Is hyperprogressive disease a specific phenomenom of immunotherapy? 47
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer 47
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 46
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: A single-center experience and review of the literature 46
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice 45
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study 45
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors 45
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 44
Abstract 2380: The effect of metabolic alterations on chemo-immunotherapy response in non-small-cell lung cancer model 43
1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program 40
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with Nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study 36
Immunotherapy and chemo-immunotherapy for non–small cell lung cancer with novel actionable oncogenic driver alterations. 33
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 32
Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts) 31
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program 29
1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy 29
1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation 29
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials 27
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation 26
DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients 23
Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology 22
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease 22
2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma 21
P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate 19
P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors 18
Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations 14
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer 14
25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils 14
68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC 13
Paraneoplastic neurological syndromes in patients affected by SCLC: a case series 13
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study 10
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy 10
178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients 10
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations 9
Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations 9
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC 9
KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC 6
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 6
Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients 6
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers 6
1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib 5
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 5
Exploring the role of immunotherapy-based treatments for advanced non-small cell lung cancer with novel driver alterations 5
P1.15-02 Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors 5
MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173) 5
EP08.01-006 Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy 5
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis 5
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients 5
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors 4
Totale 2.533
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.861
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020139 0 0 0 0 18 25 23 19 16 21 4 13
2020/2021331 8 6 5 8 10 8 31 45 24 56 28 102
2021/2022566 15 7 27 29 72 35 28 41 29 29 139 115
2022/2023652 125 188 55 36 64 56 33 45 27 4 14 5
2023/2024455 20 26 19 38 58 72 21 22 2 95 54 28
2024/2025238 12 29 122 61 14 0 0 0 0 0 0 0
Totale 2.533